67 results
Keyword Blenrep Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Blenrep (updated)
belantamab mafodotin, Multiple Myeloma
Date of authorisation: 25/08/2020,
, 
, 
, Revision: 6, Authorised, Last updated: 09/06/2023
Blenrep Hemostatic Disorders Vascular … belantamab mafodotin Overview Blenrep is a cancer medicine used … Multiple myeloma is rare, and Blenrep was designated an ‘ A medicine … -
List item
Orphan designation: Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F for: Treatment of multiple myeloma
Date of designation: 16/10/2017, Positive, Last updated: 17/09/2020been authorised in the EU as Blenrep since 25 August 2020. Expand … Blenrep Blenrep belantamab mafodotin Humanised … the orphan designation of BLENREP at the time of marketing … -
List item
News: First antibody-drug conjugate for multiple myeloma patients with limited treatment options
CHMP, Last updated: 24/07/2020in the European Union for Blenrep (belantamab mafodotin) to … observed three months or less. Blenrep was accepted in EMA’s PRIME … patients' unmet medical needs. Blenrep has a new mechanism of action … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020
CHMP, Last updated: 24/07/2020Blenrep* … -
List item
National expert: Paul Pirson, Federal Institute for Drugs and Medical Devices (updated)
- Declaration of interests - 44.33 KB | PDF
- Curriculum Vitae - 38.04 KB | PDF
Past 01-03- 2018 30-06- 2021 GlaxoSmithKline Clinical Research Associate Blenrep Multiple myeloma Page … -
List item
National expert: Carolina Prieto Fernandez, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 39.34 KB | PDF
- Curriculum Vitae - 28.19 KB | PDF
of Belantamab Mafodotin (Blenrep) for the Treatment of Adult … -
List item
National expert: Karri Penttila, Finnish Medicines Agency (updated)
- Declaration of interests - 39.2 KB | PDF
- Curriculum Vitae - 35.16 KB | PDF
of Belantamab Mafodotin (Blenrep) for the Treatment of Adult … -
List item
Human medicine European public assessment report (EPAR): Nexpovio
Selinexor, Multiple Myeloma
Date of authorisation: 26/03/2021,, Revision: 7, Authorised, Last updated: 20/02/2023
-
List item
Human medicine European public assessment report (EPAR): Carvykti
ciltacabtagene autoleucel, Multiple Myeloma
Date of authorisation: 25/05/2022,, , , Revision: 3, Authorised, Last updated: 14/04/2023
-
List item
Human medicine European public assessment report (EPAR): Zolsketil pegylated liposomal
doxorubicin hydrochloride, liposomal, Ovarian Neoplasms; Sarcoma, Kaposi; Multiple Myeloma
Date of authorisation: 31/05/2022, Revision: 1, Authorised, Last updated: 04/05/2023 -
List item
Human medicine European public assessment report (EPAR): Abecma
idecabtagene vicleucel, Multiple Myeloma; Neoplasms; Cancer; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Infectious Mononucleosis; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases
Date of authorisation: 18/08/2021,, , , Revision: 5, Authorised, Last updated: 21/12/2022
-
List item
Human medicine European public assessment report (EPAR): Tecvayli
Teclistamab, Multiple Myeloma
Date of authorisation: 23/08/2022,, , Authorised, Last updated: 07/03/2023
-
List item
Human medicine European public assessment report (EPAR): Celdoxome pegylated liposomal
doxorubicin hydrochloride, Breast Neoplasms; Ovarian Neoplasms; Multiple Myeloma; Sarcoma, Kaposi
Date of authorisation: 15/09/2022, Revision: 1, Authorised, Last updated: 13/04/2023 -
List item
Human medicine European public assessment report (EPAR): Pepaxti
Melphalan flufenamide hydrochloride, Multiple Myeloma
Date of authorisation: 17/08/2022, Revision: 1, Authorised, Last updated: 19/12/2022 -
List item
Human medicine European public assessment report (EPAR): Sarclisa
Isatuximab, Multiple Myeloma
Date of authorisation: 30/05/2020,, Revision: 7, Authorised, Last updated: 25/04/2023
-
List item
Human medicine European public assessment report (EPAR): Thalidomide Lipomed
Thalidomide, Multiple Myeloma
Date of authorisation: 19/09/2022, Authorised, Last updated: 20/10/2022 -
List item
Human medicine European public assessment report (EPAR): Darzalex
Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016,
, , Revision: 20, Authorised, Last updated: 22/03/2023
-
List item
Human medicine European public assessment report (EPAR): Plerixafor Accord
Plerixafor, Multiple Myeloma; Hematopoietic Stem Cell Transplantation
Date of authorisation: 16/12/2022,, 
, Authorised, Last updated: 06/02/2023
-
List item
Human medicine European public assessment report (EPAR): Kyprolis
carfilzomib, Multiple Myeloma
Date of authorisation: 19/11/2015,, , Revision: 20, Authorised, Last updated: 15/06/2022
-
List item
National expert: Lucia Lopez-Anglada Fernandez, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 39.72 KB | PDF
- Curriculum Vitae - 42.78 KB | PDF
-
List item
Human medicine European public assessment report (EPAR): Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto)
lenalidomide hydrochloride monohydrate, Multiple Myeloma; Myelodysplastic Syndromes; Lymphoma, Follicular; Lymphoma, Mantle-Cell
Date of authorisation: 11/02/2021,, Revision: 3, Authorised, Last updated: 22/12/2021
-
List item
Human medicine European public assessment report (EPAR): Lenalidomide Krka d.d.
lenalidomide hydrochloride hydrate, Multiple Myeloma; Lymphoma, Follicular; Myelodysplastic Syndromes
Date of authorisation: 11/02/2021,, Revision: 2, Authorised, Last updated: 17/12/2021
-
List item
Human medicine European public assessment report (EPAR): Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)
lenalidomide hydrochloride monohydrate, Multiple Myeloma; Lymphoma, Follicular
Date of authorisation: 11/02/2021,, Revision: 3, Authorised, Last updated: 17/12/2021
-
List item
National expert: Christian Gisselbrecht, National Agency For The Safety Of Medicine And Health Products (updated)
- Declaration of interests - 40.81 KB | PDF
- Curriculum Vitae - 53.77 KB | PDF
of Belantamab Mafodotin (Blenrep) for the Treatment of Adult … -
List item
List of medicines under additional monitoring (updated)
Last updated: 30/05/2023